Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure (NYHA Class I-III). Effect on HbA1c and overall safety and tolerability will also be assessed.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Vildagliptin

Criteria

Inclusion Criteria:

• Patients with T2DM, diagnosed at least 3 months prior to Visit 1

• CHF (NYHA Class I, Class II, or Class III) at Visit 1

• LVEF < 40%

Exclusion Criteria:

• Pregnant or lactating female

• FPG ≥ 270 mg/dL (≥15 mmol/L)